Feature | July 23, 2013

AngioScore Completes Enrollment in Drug-Coated Scoring Balloon Study

AngioScore AngioSculpt Drug-Coated Scoring Catheter FIH Study

July 23, 2013 — AngioScore Inc. announced the completion of enrollment in the Drug-Coated AngioSculpt Scoring Balloon Catheter First-in-Human (FIH) Study (PATENT-C). AngioScore anticipates that preliminary data from this study will be available for presentation at the Transcatheter Cardiovascular Therapeutics (TCT) conference to be held this fall in San Francisco.

This FIH trial of a novel drug-coated scoring balloon enrolled 61 patients with coronary in-stent restenosis (ISR) at five renowned international sites, four in Germany and one in Brazil. The study is led by Bruno Scheller, M.D., professor of interventional cardiology at Saarland University Hospital, Homburg, Germany, who along with Professor Ulrich Speck of the Charite Hospital in Berlin, is one of the preeminent pioneers in the rapidly developing field of drug-coated balloons for the treatment of coronary and peripheral artery disease. “The development of a Drug-Coated AngioSculpt represents a potential major advance in the percutaneous treatment of endovascular disease,” said Scheller. “I am honored to lead this important study and to collaborate with such an internationally prominent interventional cardiologist as Professor Alexandre Abizaid and his team at Dante Pazzanese Institute of Cardiology in Sao Paulo, Brazil.”

“The AngioSculpt Scoring Balloon Catheter represents a significant advance in the treatment of challenging coronary and peripheral lesions. AngioScore’s PMA clinical trial and other studies demonstrated the ability of the AngioSculpt to achieve more predictable luminal expansion, avoid slippage or geographic miss and result in a low rate of dissection. We believe these features may be particularly valuable in the field of drug-coated balloons by ensuring more precise delivery of the anti-proliferative drug and potentially obviating the need to deploy a stent in a significant proportion of lesions,” said Gary Gershony, M.D., co-founder and chief medical officer of AngioScore. “Extensive pre-clinical studies performed by Speck and Scheller have preliminarily demonstrated the safety of a drug-coated AngioSculpt and its potential ability to have a profound effect on preventing restenosis. These studies have laid the groundwork for this FIH clinical trial.”

The drug-coated AngioSculpt FIH study was designed as a randomized controlled trial comparing the recently developed drug-coated AngioSculpt with the commercially available uncoated version of the AngioSculpt in patients presenting with significant restenosis in a previously implanted coronary bare metal stent. Patients will undergo follow-up coronary angiography at six months to compare the rate of recurrent restenosis and late lumen loss (LLL) in both treatment arms. Additional study endpoints include the rate of major adverse cardiovascular events (MACE), clinically driven target lesion revascularization (TLR) and stent thrombosis for up to two years following the index procedure. All angiograms will be analyzed by an independent core laboratory at the Cardiovascular Research Foundation in New York, N.Y.

More than 3 million coronary and peripheral angioplasty procedures are performed annually worldwide. A majority of these lesions are treated with permanent stents that often require concomitant treatment with a prolonged course of dual anti-platelet therapy to avoid the potentially life-threatening complication of stent thrombosis, adding significantly to the procedural costs and to the long-term risk of serious bleeding complications. Additionally, there are important lesion subsets that may not be suitable for stenting including side-branch vessels of bifurcations, smaller-caliber vessels, restenosed stents and certain peripheral vessels. A drug-coated AngioSculpt may allow a shortened course of dual anti-platelet therapy and has the potential to transform the treatment of many patients presenting with these challenging lesions.

The AngioSculpt Scoring Balloon Catheters represent the next generation in angioplasty catheters for both coronary and peripheral artery disease. The AngioSculpt catheters provide the versatility and effectiveness of a new technology together with the simplicity and deliverability of traditional high-performance balloon catheters.

AngioSculpt catheters have now been used in more than 250,000 procedures worldwide and have achieved an outstanding safety and performance record in the treatment of both coronary and peripheral artery disease.

The Drug-Coated AngioSculpt Scoring Balloon Catheter is an investigational device, limited by applicable law to investigational use and not available for sale.

For more information: www.angioscore.com

Related Content

smartphones, hospital tranfers, heart attack patients, JACC study, South Korea
News | Mobile Devices| September 23, 2016
Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for...
Robert M. Califf, FDA commissioner, future of cardiovascular medicine, JACC column
News | Business| September 23, 2016
Technology advances coupled with increased use of social media and personal devices could offer new possibilities for...
Medtronic, In.Pact Admiral drug-coated balloon, trial data, VIVA
News | Drug-Eluting Balloons| September 22, 2016
New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the durability, consistency...
4Tech, TriCinch TTVR, transcather tricuspid valve repair device, first implant
News | Heart Valve Technology| September 22, 2016
4Tech Inc. announced that its TriCinch device has been used in the world’s first-ever successful transcatheter...
Transesophageal Echo, TEE. Interventional echocardiography, interventional echo, Philips, CX50

Transesophageal echo (TEE) has become an essential part of the new transcatheter structrual heart therapies, giving rise to a new sub-speciality of interventional echocardiography.  

Feature | Cath Lab Navigation Aids| September 21, 2016 | Dave Fornell
The rapid growth of transcatheter structural heart procedures and the need for increased use of echocardiography as a
Sponsored Content | Videos | Inventory Management| September 21, 2016
With bundled payments putting increased pressure on hospitals to manage supply costs while providing quality patient
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
Teleflex, AVA 2016 Congress, Association for Vascular Access
News | Vascular Access| September 20, 2016
September 20, 2016 — Teleflex Inc.
Edwards sapien, intermediate risk patients, CE mark
News | Heart Valve Technology| September 20, 2016
September 19, 2016 — Edwards Lifesciences received European CE mark to expand use of the Edwards Sapien 3 transcathet
Shockwave medical, lithoplasty
News | Cath Lab| September 19, 2016
September 19, 2016 — Shockwave Medical announced positive clinical results from the pooled DISRUPT PAD Study, a singl
Overlay Init